Publication Details
Abstract
Acinetobacter baumannii is an opportunistic pathogen known for its remarkable ability to form biofilms, contributing significantly to its persistence in hospital environments and resistance to antimicrobial treatments. Biofilm formation in A. baumannii is a complex, genetically regulated process involving a network of genes responsible for adhesion, extracellular matrix production, and stress response. Key genetic determinants include the bap gene, which encodes the biofilm-associated protein, the csu operon involved in pilus-mediated surface attachment, and the ompA gene, which enhances adhesion and immune evasion. Additionally, quorum sensing regulators such as abaI play a crucial role in coordinating biofilm development. The presence of these genetic elements not only enhances the pathogen’s ability to colonize medical devices but also significantly increases its tolerance to antibiotics, leading to chronic infections, particularly in immunocompromised patients. Clinically, biofilm formation in A. baumannii is associated with ventilator-associated pneumonia, bloodstream infections, and wound infections, posing a major challenge for treatment. Conventional antibiotics often fail to penetrate biofilms effectively, necessitating alternative therapeutic approaches such as quorum sensing inhibitors, biofilm-disrupting agents, and combination therapies. Understanding the genetic basis of biofilm formation is crucial for developing targeted interventions to mitigate A. baumannii-associated infections. Future research should focus on novel anti-biofilm strategies, including gene-targeting therapies and the use of biofilm-resistant biomaterials in medical devices. Addressing this issue is essential for improving patient outcomes and controlling the spread of multidrug-resistant A. baumannii in healthcare settings.